Early and Maintained Treat-to-Target Response with Ixekizumab up to 5 Years in Moderate-to-Severe Psoriasis: Analysis of the UNCOVER-3 Study.

Taltz (ixekizumab) - Eli Lilly

http://www.ncbi.nlm.nih.gov/pubmed/42749063

Andreas Pinter; April Armstrong; Jose-Manuel Carrascosa; Joseph F Merola; Konstantinos Fotiou; Marcus Ngantcha; Masaru Honma; Matteo Megna; Rukhsar Chughtai; Silvia Sabatino; Xiaoyong Man

Sep 17, 2026